CADx gains approvable letter:
This article was originally published in Clinica
Executive Summary
CADx Medical Systems looks set to become the second firm to gain US approval to sell its computer-aided detection (CAD) system for use with mammography, after the company received an approvable letter from the FDA for its Second Look CAD product. Marketing clearance for the device is subject to final labelling discussions with the FDA. A competing firm, R2 Technology, gained FDA approval for its mammography CAD product, ImageChecker, in 1998.
You may also be interested in...
Xbrane Assembles The Troops As FDA Says No To Lucentis Biosimilar
Xbrane Biopharma was riding the crest of a wave with the EU launch of its biosimilar to Lucentis, following years of toil and investment. However, plans to roll out the product in the US will have to be pushed back – likely – into the middle of 2025, following a US FDA complete response letter.
UK MHRA Updates Assistive Tech And Borderline Regulations
Device classification themes were uppermost in April for the UK regulator, which issued key guidance in two areas prone to complexities. It also contributed to the MedTech Directorate’s one-year progress report.
Fujifilm Demonstrates Health Specialism With European HealthTech Spinout
From X-ray film in 1936 to the world’s first digital X-ray system in 1983, Fujifilm has a long heritage in medical diagnostics.